Quantum-Si incorporated (QSI) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates positive developments such as successful prototype milestones, new product launches, and a strong financial position. The Q&A section reveals consistent consumable sales and strategic planning for the Proteus launch, despite some uncertainties in customer acquisition models and NIH funding. Overall, the company's strategic focus on product development and a strong balance sheet suggest a positive outlook, likely leading to a stock price increase.
Key Financial Performance
Revenue for Q4 2025 $451,000, impacted by capital sales headwinds in the market.
Gross profit for Q4 2025 $122,000, resulting in a gross margin of 27%. Gross margin was impacted by revenue mix with a higher proportion of consumable revenue to hardware and certain inventory adjustments.
Full year 2025 revenue $2.4 million, with a gross profit of $1.2 million and a gross margin of 47%. Full year gross margin benefited from a higher mix of instrument sales and a lower overall impact from inventory adjustments compared to Q4.
GAAP total operating expenses for Q4 2025 $21.2 million, compared to $31.3 million in Q4 2024. Adjusted operating expenses were $18.3 million, compared to $26.7 million in the prior year quarter.
Full year 2025 GAAP total operating expenses $117.3 million, compared to $110.2 million in 2024. Adjusted operating expenses were $86.3 million, down from $99 million in the prior year. The reduction reflects cost discipline, focused R&D activities, and targeted resource allocation towards advancing the Proteus platform.
Dividend and interest income for Q4 2025 $2.2 million, consistent with the prior year quarter.
Full year 2025 dividend and interest income $9.7 million, compared to $11.4 million in 2024. The decrease reflects lower interest rates and changes in invested balances.
Cash, cash equivalents, and investments as of December 31, 2025 $215.8 million.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Proteus Development: Focus on Proteus development for a strong commercial ramp in 2027. Proteus surpasses first-generation technology across all key performance metrics. Proteus list price announced at $425,000.
Platinum Pro Instrument: Capital sales of Platinum Pro will be limited in 2026 due to focus on Proteus launch.
Version 3 Library Prep Kit: Launched in Q4 2025, enabling sequencing with as little as 1-2 nanograms of protein, a 100-fold reduction in input requirements.
Expanded Instrument Acquisition Options: Program launched in 2025 allowing customers to acquire instruments without upfront capital. Secured 17 new customers across academic labs, pharma, and biotech.
New Applications for Technology: Manuscripts published showcasing applications in clinical proteomics and rapid pathogen detection, expanding potential market beyond basic research.
Cost Discipline: Reduced adjusted operating expenses to $86.3 million in 2025 from $99 million in 2024.
Revenue and Gross Margin: 2025 revenue was $2.4 million with a gross margin of 47%. Q4 2025 revenue was $451,000 with a gross margin of 27%.
Transition Year in 2026: 2026 positioned as a transition year focusing on Proteus development and market preparation, with deliberate trade-offs prioritizing long-term platform adoption over near-term revenue.
Financial Strength: $215.8 million in cash and investments as of December 31, 2025, supporting operations into Q2 2028.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Capital Sales Headwinds: The company faces challenges in capital sales, particularly with the first-generation Platinum Pro instrument, due to market conditions and a deliberate focus on preparing for the Proteus launch. This has resulted in limited new capital sales and a reliance on consumable utilization for revenue.
NIH Funding Delays and Budget Concerns: Delays in NIH funding, concerns over the NIH budget, and indirect reimbursement rates have created uncertainty, impacting customer capital budgets and delaying purchasing decisions.
Proteus Development and Launch Risks: The company is heavily focused on the development and launch of the Proteus platform, which involves significant R&D investment and operational focus. Any delays or issues in development, manufacturing, or market readiness could adversely impact the anticipated commercial ramp in 2027.
Financial Discipline and Cash Usage: The company is operating with a high level of fiscal discipline but acknowledges that the focus on Proteus in 2026 will impact top-line results. Cash usage is projected to be $93 million or less, with a need to manage costs effectively to support operations into 2028.
Regulatory and Litigation Costs: The company incurred charges related to legacy litigation matters and a leased facility termination, which could pose ongoing financial risks if similar issues arise in the future.
Market Preparation Challenges: The deliberate focus on preparing the market for Proteus has led to trade-offs, such as embedding upgrade paths into existing units, which impacts near-term revenue. Customer delayed purchases as they plan for Proteus also contribute to revenue challenges.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations for 2026: The company anticipates total revenue to be approximately $1 million in 2026, reflecting a deliberate transition year focused on preparing for the Proteus launch.
Proteus Launch and Market Preparation: Proteus is expected to launch at the end of 2026. The company is focusing on market preparation, including customer engagement and data generation, to ensure a strong commercial ramp in 2027 and beyond.
Capital Sales and Consumable Revenue: Capital sales of the first-generation Platinum Pro instrument are expected to be very limited in 2026. Revenue will primarily be driven by consumable utilization from the installed base and some new placements.
Proteus Pricing Strategy: The list price for Proteus has been announced at $425,000, aiming to balance premium value and accessibility to a larger customer base.
R&D and Innovation Focus: The company is prioritizing Proteus development, including improving proteome coverage, sequencing read length, and library prep capabilities. Progress is ahead of expectations in detecting amino acids and sequencing read length.
Financial Guidance and Cash Usage: Adjusted operating expenses are expected to be $98 million or less, with total cash usage of $93 million or less in 2026. The company has $215.8 million in cash and investments, supporting operations into Q2 2028.
Long-Term Strategy and Financial Position: The company is prioritizing long-term platform adoption over near-term revenue maximization, leveraging financial strength to fund development and commercialization activities without near-term capital decisions.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend and interest income: Dividend and interest income was $2.2 million in the fourth quarter of 2025, consistent with the prior year quarter and $9.7 million for the full year of 2025 compared to $11.4 million in 2024. The year-over-year decrease for the full year reflects lower interest rates and changes in invested balances.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the trends in consumable usage within the installed base?
A:Customers are purchasing consumables at a consistent rate. Academic customers tend to purchase episodically, while other market segments have a more consistent order pattern. The company expects a more than 25% increase in the number of consumable kits being run by customers this year.
Q:Should we expect very few placements and most revenue from consumables and service revenue in 2026?
A:Yes, most revenue is expected to come from consumables and service revenue. There will be a modest number of Platinum Pro machines purchased for capital, and some customers may request credits for future Proteus machines, which could alter short-term revenue recognition.
Q:How should we think about the launch curve for Proteus in 2027?
A:The launch curve will involve distinct customer groups: existing Platinum users transitioning to Proteus, new customers attracted by Proteus' capabilities, and channel partners in global markets. The company is working to build momentum and ensure an efficient commercialization process.
Q:Does the $98 million guidance for operating expenses include stock-based compensation?
A:No, the $98 million guidance for operating expenses excludes stock-based compensation. It represents an adjusted operating expense number focused on cash-oriented expenses.
Q:Does announcing the price point for Proteus indicate secured preorders or letters of intent?
A:No, there are no secured orders yet. The price point was announced to help customers with capital planning and grant applications, ensuring they allocate the right amount of funds for future purchases.
Q:Will customers likely use lease purchase methods for Proteus, or will they purchase it for cash?
A:Currently, only direct capital purchases are planned for Proteus. The company is monitoring factors like NIH budget stability and customer capital planning cycles to determine if other acquisition models will be introduced.
Q:How many amino acids will Proteus detect at launch, and what is the progress on this front?
A:Proteus is expected to detect 18 amino acids at launch, with plans to demonstrate 20 by the end of the year. Progress in detecting all 20 amino acids could accelerate their inclusion in kits sooner than anticipated.
Q:What is the overlap between the existing customer base and the potential customer base for Proteus?
A:There is some overlap, particularly among core labs and proteomics centers of excellence. Smaller individual investigator labs may not transition to Proteus due to funding constraints, but some may pool resources to purchase the system.
Q:What are the top applications for Proteus that could drive its adoption?
A:Key applications include working with complex biological samples, post-translational modifications (PTMs), and translational labs for biomarker validation. These capabilities align with the needs of core labs and high-volume research sites.
Q:Will the company increase its field sales force in preparation for the Proteus launch?
A:Yes, the company plans to augment its commercial team to be launch-ready for Proteus by the end of 2026.
Q:What feedback led to the decision to focus on Proteus and slow down Platinum sales?
A:Feedback indicated that some customers prefer to wait for Proteus due to its advanced capabilities. The company is using placement programs to engage customers who can benefit from Platinum now and transition to Proteus later.
Q:What gives the company confidence in the $425,000 price point for Proteus?
A:The price point is competitive compared to high-end mass spectrometry machines, which can cost $850,000 to over $1 million. Proteus' capabilities, such as PTMs and complex sample analysis, justify the price for core labs and high-volume sites.
Q:Will Proteus launch with a reagent rental program?
A:No, Proteus will initially launch with direct capital sales only. The company will evaluate market feedback to decide if other acquisition models should be introduced.
Q:What are the risks to launching Proteus in 2026?
A:The main risks involve optimizing performance, reliability, and manufacturing quality. However, the technical innovation phase is complete, and any delays would likely be short-term.
Q:Is there any risk or uncertainty regarding NIH academic funding this year?
A:The company has not received specific feedback from customers about NIH funding uncertainties. They are more focused on customers' financial calendars and capital budgeting cycles.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer to the question about the overlap between the existing customer base and the potential customer base for Proteus. They provided qualitative insights but did not quantify the overlap. Additionally, they did not provide specific guidance on gross margins for 2026, citing various factors that could impact margins.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Day demonstrating
Day detail
PTM analysis
Platinum Pro
Proteus development
Proteus launch
capital sale
channel partner
component
development effort
development market
enrichment
event Proteus
feasibility
focus Proteus
generation
goal
intelligence tool
length
line result
list price
manuscript publication
paper
path
peptide
piece
placement
platform number
prep version
program lab
progress plan
prospect Proteus
proteome coverage
reduction input
throughput
today program
utilization
version library
QSI Transcript
Quantum-Si incorporated (QSI) Q4 2025 Earnings Call Transcript
Positive3-4
The earnings call summary indicates positive developments such as successful prototype milestones, new product launches, and a strong financial position. The Q&A section reveals consistent consumable sales and strategic planning for the Proteus launch, despite some uncertainties in customer acquisition models and NIH funding. Overall, the company's strategic focus on product development and a strong balance sheet suggest a positive outlook, likely leading to a stock price increase.
Quantum-Si incorporated (QSI) Q3 2025 Earnings Call Transcript
Unknown11-5
The earnings call presents mixed signals: revenue has decreased, and there are uncertainties in NIH funding, but there is optimism about product launches and market opportunities. The Q&A reveals management's evasiveness on key issues, adding uncertainty. Despite financial constraints, cost controls are evident. Strong financial metrics are offset by weak guidance and lack of clarity, leading to a neutral sentiment.
Quantum-Si incorporated (QSI) Q2 2025 Earnings Call Transcript
Positive8-5
The earnings call summary and Q&A reveal strong financial performance with an 84% revenue increase and a 58% gross margin. Management is optimistic about growth, especially in Q4, and is implementing flexible sales models to overcome capital constraints. The company is focused on innovation and market expansion, particularly in pharma and biotech. Despite some unclear responses, the overall sentiment is positive, supported by strategic product launches and a solid cash position. The stock price is likely to experience a positive movement in the next two weeks.
Quantum-Si incorporated (NASDAQ:QSI) Q1 2025 Earnings Call Transcript
Unknown5-17
The earnings call reveals mixed signals: strong revenue growth and international expansion are positive, but uncertainties in NIH funding and a slowdown in the U.S. academic market are concerning. The Q&A session highlights confidence in the biopharma market and positive feedback on product launches, but unclear responses on tariffs and a dip in dividend income raise caution. With a robust cash position and strategic partnerships, the short-term stock reaction is likely neutral, balancing positive growth against market uncertainties.
QSI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
